This Executive Summary of the Global Strategy for the Diagnosis,
Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily
on the revised and novel parts of the document.
The most significant
changes include:
i) the assessment of COPD has been refined to separate
the spirometric assessment from symptom evaluation. ABCD groups are now
proposed to be derived exclusively from patient symptoms and their
history of exacerbations;
ii) for each of the groups A to D, escalation
strategies for pharmacological treatments are proposed;
iii) the concept
of de-escalation of therapy is introduced in the treatment assessment
scheme;
iv) nonpharmacologic therapies are comprehensively presented
and;
v) the importance of comorbid conditions in managing COPD is
reviewed.
Link to full text:
